Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Hims & Hers Health, Inc. (NYSE:HIMS) has been assigned an average rating of “Moderate Buy” from the sixteen ratings firms that are covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $20.21.

Several equities analysts have recently commented on HIMS shares. Piper Sandler reaffirmed a “neutral” rating and set a $18.00 target price on shares of Hims & Hers Health in a report on Tuesday, August 6th. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Bank of America raised their target price on Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, October 21st. TD Cowen upped their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Finally, Needham & Company LLC started coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective on the stock.

Insider Activity at Hims & Hers Health

In other news, insider Michael Chi sold 7,500 shares of the business’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $22.20, for a total transaction of $166,500.00. Following the sale, the insider now directly owns 193,980 shares of the company’s stock, valued at $4,306,356. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, insider Michael Chi sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $22.20, for a total value of $166,500.00. Following the completion of the sale, the insider now owns 193,980 shares in the company, valued at approximately $4,306,356. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the transaction, the chief executive officer now owns 33,502 shares in the company, valued at approximately $487,789.12. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 841,076 shares of company stock valued at $14,759,219 over the last ninety days. Insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Hims & Hers Health by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after purchasing an additional 136,907 shares in the last quarter. Renaissance Technologies LLC raised its position in Hims & Hers Health by 113.1% during the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after acquiring an additional 3,205,108 shares in the last quarter. Farallon Capital Management LLC raised its position in Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after acquiring an additional 1,634,000 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Hims & Hers Health by 67.5% in the second quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock valued at $13,701,000 after acquiring an additional 273,473 shares during the last quarter. Finally, M&G Plc bought a new stake in Hims & Hers Health in the first quarter worth approximately $8,232,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $21.73 on Friday. The company has a market cap of $4.67 billion, a PE ratio of -2,173.00 and a beta of 1.06. Hims & Hers Health has a 12 month low of $5.65 and a 12 month high of $25.74. The company has a fifty day moving average price of $17.59 and a two-hundred day moving average price of $17.85.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. The business had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company’s quarterly revenue was up 51.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.03) EPS. Equities research analysts anticipate that Hims & Hers Health will post 0.22 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.